文献速递淋巴瘤

CALGB 50604:基于中期PET风险适应治疗非巨块型早期霍奇金淋巴瘤

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
PubMed 文献 · Blood · 2018-07-26

这项2期试验入组164例初治非巨块型I/II期霍奇金淋巴瘤患者,中期PET阴性者接受4周期ABVD,阳性者接受2周期强化BEACOPP加受累野放疗。中位随访3.8年,PET阴性组3年无进展生存率为91%,PET阳性组为66%,风险比为3.84。

要点

  • 中期PET阴性(Deauville 1–3分)的早期非巨块型霍奇金淋巴瘤患者接受4周期ABVD可获持久缓解。
  • PET阴性组3年无进展生存率为91%,PET阳性组为66%,风险比3.84(95%CI 1.50–9.84,P=.011)。
  • PET阳性患者接受2周期强化BEACOPP加3060-cGy受累野放疗。

核心结论

  • 4周期ABVD可使多数中期PET阴性的早期非巨块型霍奇金淋巴瘤患者获得持久缓解。

研究设计与样本

  • 这是一项2期试验,于2010年5月15日至2013年2月21日入组164例既往未治疗的I/II期非巨块型霍奇金淋巴瘤患者,最终分析纳入149例。
  • 患者接受2周期ABVD后行PET/CT,Deauville 1–3分为阴性(≤肝脏摄取),基于中心 review 判定。
  • PET阴性患者再接受2周期ABVD,PET阳性患者接受2周期剂量强化BEACOPP加3060-cGy受累野放疗。
  • 主要目标是确定PET阴性组的3年无进展生存率。

主要发现

  • 135例(91%)为中期PET阴性,14例(9%)为PET阳性。
  • 中位随访3.8年,PET阴性组估计3年无进展生存率为91%,PET阳性组为66%(风险比3.84;95%CI 1.50–9.84;P=.011)。
  • 有1例死亡,原因为自杀。

关键数值与推荐

  • Deauville 1–3分(≤肝脏摄取)为中期PET阴性,基于中心 review 判定。
  • PET阴性患者接受4周期ABVD(2周期后PET阴性再接受2周期)。
  • PET阳性患者接受2周期剂量强化BEACOPP加3060-cGy受累野放疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A negative interim positron emission tomography/computerized tomography (PET/CT) after 1 to 3 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with newly diagnosed, nonbulky stage I or II Hodgkin lymphoma (HL) predicts a low relapse rate. This phase 2 trial was designed to determine if a population of patients with early-stage disease can be treated with short-course ABVD without radiation therapy (RT) on the basis of a negative interim PET/CT, thereby limiting the risks of treatment. Between 15 May 2010 and 21 February 2013, 164 previously untreated patients with nonbulky stage I/II HL were enrolled, and 149 were included in the final analysis. Patients received 2 cycles of ABVD followed by PET. Deauville scores 1 to 3 were negative (≤ liver uptake) based on central review. PET- patients received 2 more cycles of ABVD, and PET+ patients received 2 cycles of dose-intense bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (escalated BEACOPP) plus 3060-cGy involved-field RT. The primary objective was to determine 3-year progression-free survival (PFS) for the PET- group. One hundred thirty-five patients (91%) were interim PET-, and 14 patients (9%) were PET+ With median follow-up time of 3.8 years, the estimated 3-year PFS was 91% for the PET- group and 66% for the PET+ group (hazard ratio, 3.84; 95% confidence interval, 1.50-9.84; P = .011). There was 1 death as a result of suicide. Four cycles of ABVD resulted in durable remissions for a majority of patients with early-stage nonbulky HL and a negative interim PET. This trial was registered at www.clinicaltrials.gov as #NCT01132807.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Straus DJ, Jung SH, Pitcher B, et al. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood. 2018. PMID: 30049811. doi:10.1182/blood-2018-01-827246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。